NaV1.9 | sodium voltage-gated channel alpha subunit 11
Family:
Sodium channels
Subgroups:
NaV1.1-1.9
Topology:
Alpha subunits consist of four homologous domains (I-IV) with six transmembrane alpha helices (S1–S6) and a pore-forming loop. One a subunit may associate with 1 or 2 b subunits to make up the channel.
NaV1.9: Background Information
NaV1.9 is largely expressed in small-diameter nociceptors of the dorsal root ganglion and trigeminal ganglion neurons, but is also found in intrinsic myenteric neurons. Like NaV1.7 and NaV1.8, NaV1.9 plays a role in pain perception, having been linked to the perception of inflammatory, neuropathic, and cold-related pain. It does this primarily through its ability to lower the threshold potential of the neuron, allowing for an increase in action potential firing that leads to hyperexcitability of the neuron and increased pain perception.This channel NaV1.9 is a TTX-resistant sodium channel.
Gene:
SCN11A
Human Protein:
UniProt Q9UI33
Tissue:
Brain, olfactory bulb, hippocampus, cerebellar cortex, spinal cord, small intestine, spleen, testis, bladder, and placenta
Function/ Application:
Excitability of neurons (lowering the threshold potential), nociceptive transmission
Pathology:
Episodic pain syndrome, familial, 3 (FEPS3), Pathogenic Neuropathy hereditary sensory and autonomic 7 (HSAN7), Diarrhea, Dysautonomia, Hyperhidrosis
Accessory subunits:SCN1B, SCN2B and SCN3B
Interaction:
Calmodulin 1, Calmodulin 2, Calmodulin 3, spectrin, Neurofascin, CACNA1H, CACNA1I, Kinesin Family Member 5C, Ryanodine Receptor 1, Ryanodine Receptor 2
Modulator:
Tetracaine, Nifedipine, Carbamazepine, Vinpocetine, Amiloride hydrochloride
Assays:
Patch Clamp: whole cell, perforated patch
Particularities:
NaV channel analysis requires GigaOhm seals and a stable and low access resistance
Recommended Reviews:International Union of Pharmacology. XLVII. Nomenclature and Structure-Function Relationships of Voltage-Gated Sodium Channels. Pharmacol Rev 57: 397–409, Catterall, et al. 2005
Data and Applications
NaV1.9 - Pharmacology
SyncroPatch 384/768 PE (a predecessor model of the SyncroPatch 384) data and applications:
Cells were kindly provided by Icagen.
Screenshots of the PatchControl 384 software showing hNaV1.9 current traces in response to a voltage step protocol. Measured on the SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) using perforated patch methodology (Escin) and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was 86%. NaV1.9 is TTX insensitive. The IC50 value of lidocaine of the peak current was determined as 350 µM (Literature: 356 µM), the IC50 value of tetracaine of the peak current was determined as 12.5 µM (Literature: 32 µM).
Application Notes
hNaV1.9 - "High Throughput Pharmacology of NaV1.9 Channels on Nanion’s SyncroPatch 384"
SyncroPatch 384 application note: 
(1.6 MB)
Cells kindly provided by Icagen, Inc., USA.
Webinars and Movies
Posters
2018 - Investigating pain pathways by inhibition of voltage-gated sodium channels
SyncroPatch 384PE (a predecessor model of the SyncroPatch 384) and 
Patchliner poster, FENS Meeting 2018 (2.5 MB)
Publications
2022 - The suitability of high throughput automated patch clamp for physiological applications
SyncroPatch 384 Publication in The Journal of Physiology (2022)
Authors:
Obergrussberger A., Rinke-Weiß I., Goetze T.A., Rapedius M., Brinkwirth N., Becker N., Rotordam M.G., Hutchison L., Madau P, Pau D, Dalrymple D., Braun N., Friis S., Pless S.A., Fertig N.
2021 - The insecticide deltamethrin enhances sodium channel slow inactivation of human Nav1.9, Nav1.8 and Nav1.7
SyncroPatch 384i (a predecessor model of the SyncroPatch 384) Publication in Toxicology and Applied Pharmacology (2021)
Authors:
Bothe S.N., Lampert A.